- Investing Ideas
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
6
Companies with a Value score of at least 3, ordered by Value score
6 companies
Bavarian Nordic
Market Cap: DKK 14.8b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 193.30
7D
7.0%
1Y
-18.6%
Novo Nordisk
Market Cap: DKK 1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NOVO B
DKK 299.45
7D
-0.02%
1Y
-13.4%
H. Lundbeck
Market Cap: DKK 42.0b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 42.46
7D
1.9%
1Y
9.2%
H. Lundbeck
Market Cap: DKK 42.0b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 41.95
7D
18.3%
1Y
28.5%
Gubra
Market Cap: DKK 6.5b
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
GUBRA
DKK 395.00
7D
4.9%
1Y
11.4%
Strategic Partners
Market Cap: DKK 28.8m
Does not have significant operations.
STRAP
DKK 690.00
7D
-1.4%
1Y
-31.3%